Core Viewpoint - LIR Life Sciences Corp. has launched a controlled comparative animal study to evaluate a needle-free transdermal delivery system for second generation GLP/GIP-based obesity therapies, marking a significant advancement in its transdermal platform from design to functional testing [1] Group 1 - The study focuses on cell-penetrating peptide (CPP) mediated delivery methods [1] - This in vivo study will utilize a small animal model for functional testing [1] - The initiative represents an important step in the development of obesity therapies [1]